Skip to main content
Top
Published in: Tumor Biology 2/2011

01-04-2011 | Research Article

A critical role of Sp1 transcription factor in regulating the human Ki-67 gene expression

Authors: Hui Tian, Guo-Wei Qian, Wang Li, Fei-Fei Chen, Jie-Hui Di, Bao-Fu Zhang, Dong-Sheng Pei, Ping Ma, Jun-Nian Zheng

Published in: Tumor Biology | Issue 2/2011

Login to get access

Abstract

Ki-67 plays a crucial role in cell proliferation as well as maintenance or regulation of cell division. The mechanism governing the Ki-67 gene expression remains unknown. Thus, we cloned the core promoter of the human Ki-67 gene and further investigated its transcriptional regulation. The putative Sp1 binding sites were confirmed by electrophoretic mobility shift assay together with an anti-Sp1 antibody-mediated supershift assay. Deletion mutagenesis and firefly luciferase reporter gene assay demonstrated the essential contribution of Sp1 on transcriptional activation of the Ki-67 gene. In this study, we first confirm that there are three Sp1 binding sites in the Ki-67 core promoter. Two Sp1 sites (one at position −159 to −145 nt and the other at position −14 to +12 nt) are mainly involved in transcriptional regulation of the Ki-67 gene. Overexpression of Sp1 can enhance the Ki-67 promoter activity. However, down-regulation of Sp1 expression using siRNA-Sp1 and mithramycin effectively inhibits the Ki-67 gene transcription. Our results suggest that Sp1 is essential for basal promoter activity of the human Ki-67 gene. Inhibition of the Ki-67 transcriptional activity through abolishment of Sp1 may provide the useful prospect for gene therapy.
Literature
1.
go back to reference Duchrow M, Schlueter C, Wohlenberg C, Flad HD, Gerdes J. Molecular characterization of the gene locus of the human cell proliferation-associated nuclear protein defined by monoclonal antibody Ki-67. Cell Prolif. 1996;29:1–12.CrossRefPubMed Duchrow M, Schlueter C, Wohlenberg C, Flad HD, Gerdes J. Molecular characterization of the gene locus of the human cell proliferation-associated nuclear protein defined by monoclonal antibody Ki-67. Cell Prolif. 1996;29:1–12.CrossRefPubMed
2.
go back to reference MacCallum DE, Hall PA. Biochemical characterization of pKi67 with the identification of a mitotic-specific form associated with hyperphosphorylation and altered DNA binding. Exp Cell Res. 1999;252:186–98.CrossRefPubMed MacCallum DE, Hall PA. Biochemical characterization of pKi67 with the identification of a mitotic-specific form associated with hyperphosphorylation and altered DNA binding. Exp Cell Res. 1999;252:186–98.CrossRefPubMed
3.
go back to reference Schlüter C, Duchrow M, Wohlenberg C, Becker MH, Key G, Flad HD, et al. The cell proliferation associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J Cell Biol. 1993;123:513–22.CrossRefPubMed Schlüter C, Duchrow M, Wohlenberg C, Becker MH, Key G, Flad HD, et al. The cell proliferation associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J Cell Biol. 1993;123:513–22.CrossRefPubMed
4.
go back to reference MaCallum DE, Hall PA. Biochemical characterization of pKi-67 with the identification of a mitotic-specific form association with hyperphosphorylation and altered DNA binding. Exp Cell Res. 1991;52:186–98. MaCallum DE, Hall PA. Biochemical characterization of pKi-67 with the identification of a mitotic-specific form association with hyperphosphorylation and altered DNA binding. Exp Cell Res. 1991;52:186–98.
5.
go back to reference Kausch I, Jiang H, Ewerdwalbesloh N, Doehn C, Kruger S, Sczakiel G, et al. Inhibition of Ki-67 in a renal cell carcinoma severe combined immunodeficiency disease mouse model is associated with induction of apoptosis and tumour growth inhibition. BJU Int. 2005;95:416–20.CrossRefPubMed Kausch I, Jiang H, Ewerdwalbesloh N, Doehn C, Kruger S, Sczakiel G, et al. Inhibition of Ki-67 in a renal cell carcinoma severe combined immunodeficiency disease mouse model is associated with induction of apoptosis and tumour growth inhibition. BJU Int. 2005;95:416–20.CrossRefPubMed
6.
go back to reference Dynan WS, Tjian R. Isolation of transcription factors that discriminate between different promoters recongnized by RNA polymerase II. Cell. 1983;32:669–80.CrossRefPubMed Dynan WS, Tjian R. Isolation of transcription factors that discriminate between different promoters recongnized by RNA polymerase II. Cell. 1983;32:669–80.CrossRefPubMed
7.
go back to reference Dynan WS, Tjian R. The promoter-specific transcription factor Sp1 binds to upstream sequences in the SV40 early promoter. Cell. 1983;35:79–87.CrossRefPubMed Dynan WS, Tjian R. The promoter-specific transcription factor Sp1 binds to upstream sequences in the SV40 early promoter. Cell. 1983;35:79–87.CrossRefPubMed
9.
go back to reference Kadonaga JT, Carner KR, Masiarz FR, Tjian R. Isolation of cDNA encoding transcription factor Sp1 and functional analysis of the DNA binding domain. Cell. 1987;51:1079–90.CrossRefPubMed Kadonaga JT, Carner KR, Masiarz FR, Tjian R. Isolation of cDNA encoding transcription factor Sp1 and functional analysis of the DNA binding domain. Cell. 1987;51:1079–90.CrossRefPubMed
10.
go back to reference Endl E, Gerdes J. Post-translational modifications of the Ki-67 protein coincide with two major check points during mitosis. J Cell Physiol. 2000;182:371–80.CrossRefPubMed Endl E, Gerdes J. Post-translational modifications of the Ki-67 protein coincide with two major check points during mitosis. J Cell Physiol. 2000;182:371–80.CrossRefPubMed
11.
go back to reference Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311–22.CrossRefPubMed Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311–22.CrossRefPubMed
12.
go back to reference Takagi M, Matsuoka Y, Kurihara T, Yoneda Y. Chmadrin: a novel Ki-67 antigen-related perichromosomal protein possibly implicated in higher order chromatin structure. J Cell Sci. 1999;112:2463–72.PubMed Takagi M, Matsuoka Y, Kurihara T, Yoneda Y. Chmadrin: a novel Ki-67 antigen-related perichromosomal protein possibly implicated in higher order chromatin structure. J Cell Sci. 1999;112:2463–72.PubMed
13.
go back to reference Yang X, Su K, Roos MD, Chang Q, Paterson AJ, Kudlow JE. O-linkage of N-acetylglucosamine to Sp1 activation domain inhibits its transcriptional capability. Proc Natl Acad Sci. 2001;98:6611–6.CrossRefPubMed Yang X, Su K, Roos MD, Chang Q, Paterson AJ, Kudlow JE. O-linkage of N-acetylglucosamine to Sp1 activation domain inhibits its transcriptional capability. Proc Natl Acad Sci. 2001;98:6611–6.CrossRefPubMed
14.
go back to reference Su K, Roos MD, Yang X, Han I, Paterson AJ, Kudlow JE. An N-terminal region of Sp1 targets its proteasome dependent degradation in vitro. J Biol Chem. 1999;274:15194–202.CrossRefPubMed Su K, Roos MD, Yang X, Han I, Paterson AJ, Kudlow JE. An N-terminal region of Sp1 targets its proteasome dependent degradation in vitro. J Biol Chem. 1999;274:15194–202.CrossRefPubMed
15.
go back to reference Safe S, Abdelrahim M. Sp transcription factor family and its role in cancer. Eur J Cancer. 2005;41:2438–48.CrossRefPubMed Safe S, Abdelrahim M. Sp transcription factor family and its role in cancer. Eur J Cancer. 2005;41:2438–48.CrossRefPubMed
16.
go back to reference Safe S, Kim K. Nuclear receptor-mediated transactivation through interaction with Sp proteins. Prog Nucleic Acid Res Mol Biol. 2004;77:1–36.CrossRefPubMed Safe S, Kim K. Nuclear receptor-mediated transactivation through interaction with Sp proteins. Prog Nucleic Acid Res Mol Biol. 2004;77:1–36.CrossRefPubMed
17.
go back to reference Bouwman P, Philipsen S. Regulation of the activity of Sp1-related transcription factors. Mol Cell Endocrinol. 2002;195:27–38.CrossRefPubMed Bouwman P, Philipsen S. Regulation of the activity of Sp1-related transcription factors. Mol Cell Endocrinol. 2002;195:27–38.CrossRefPubMed
18.
19.
go back to reference Barth N, Langmann T, Scholmerich J, Schmitz G, Schaffler A. Identification of regulatory elements in the human adipose most abundant gene transcript-1 (apM-1) promoter: role of SP1/SP3 and TNF-alpha as regulatory pathways. Diabetologia. 2002;45:1425–33.PubMed Barth N, Langmann T, Scholmerich J, Schmitz G, Schaffler A. Identification of regulatory elements in the human adipose most abundant gene transcript-1 (apM-1) promoter: role of SP1/SP3 and TNF-alpha as regulatory pathways. Diabetologia. 2002;45:1425–33.PubMed
20.
go back to reference Wang LW, Wei DY, Huang SY, Peng ZH, Le XD, Wu TT, et al. Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res. 2003;9:6371–80.PubMed Wang LW, Wei DY, Huang SY, Peng ZH, Le XD, Wu TT, et al. Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res. 2003;9:6371–80.PubMed
21.
go back to reference Shi Q, Le XD, Abbruzzese JL, Peng ZH, Qian CN, Tang HM, et al. Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res. 2001;61:4143–54.PubMed Shi Q, Le XD, Abbruzzese JL, Peng ZH, Qian CN, Tang HM, et al. Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res. 2001;61:4143–54.PubMed
22.
go back to reference Chiefari E, Brunetti A, Arturi F, Bidart JM, Russo D, Schlumberger M, et al. Increased expression of AP2 and Sp1 transcription factors in human thyroid tumours: a role in NIS expression regulation. BMC Cancer. 2002;2:35.CrossRefPubMed Chiefari E, Brunetti A, Arturi F, Bidart JM, Russo D, Schlumberger M, et al. Increased expression of AP2 and Sp1 transcription factors in human thyroid tumours: a role in NIS expression regulation. BMC Cancer. 2002;2:35.CrossRefPubMed
23.
go back to reference Hosoi Y, Watanabe T, Nakagawa K, Matsumoto Y, Enomoto A, Morita A, et al. Up-regulation of DNA-dependent protein kinase activity and Sp1 in colorectal cancer. Int J Oncol. 2004;25:461–8.PubMed Hosoi Y, Watanabe T, Nakagawa K, Matsumoto Y, Enomoto A, Morita A, et al. Up-regulation of DNA-dependent protein kinase activity and Sp1 in colorectal cancer. Int J Oncol. 2004;25:461–8.PubMed
24.
go back to reference Jang SI, Steinert PM. Loricrin expression in cultured human keratinocytes is controlled by a complex interplay between transcription factors of the Sp1, CREB, AP1, and AP2 families. J Biol Chem. 2002;277:42268–79.CrossRefPubMed Jang SI, Steinert PM. Loricrin expression in cultured human keratinocytes is controlled by a complex interplay between transcription factors of the Sp1, CREB, AP1, and AP2 families. J Biol Chem. 2002;277:42268–79.CrossRefPubMed
25.
go back to reference Suzuki T, Kimura A, Nagai R, Horikoshi M. Regulation of interaction of the acetyltransferase region of p300 and the DNA-binding domain of Sp1 on and through DNA binding. Genes Cells. 2000;5:29–41.CrossRefPubMed Suzuki T, Kimura A, Nagai R, Horikoshi M. Regulation of interaction of the acetyltransferase region of p300 and the DNA-binding domain of Sp1 on and through DNA binding. Genes Cells. 2000;5:29–41.CrossRefPubMed
Metadata
Title
A critical role of Sp1 transcription factor in regulating the human Ki-67 gene expression
Authors
Hui Tian
Guo-Wei Qian
Wang Li
Fei-Fei Chen
Jie-Hui Di
Bao-Fu Zhang
Dong-Sheng Pei
Ping Ma
Jun-Nian Zheng
Publication date
01-04-2011
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 2/2011
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-010-0119-4

Other articles of this Issue 2/2011

Tumor Biology 2/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine